Tovinontrine (IMR-687) 是一种高效的选择性磷酸二酯酶 9 (PDE9)抑制剂,可用于研究镰状细胞病。抑制PDE9A1 和 PDE9A2 的IC50分别为 8.19 nM 和 9.99 nM。
生物活性 | Tovinontrine (IMR-687) is a highly potent and selectivephosphodiesterase-9 (PDE9)inhibitor specifically for the treatment of sickle cell disease.IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively[1]. |
IC50& Target | PDE9A1 8.19 nM () | PDE9A2 9.99 nM () | PDE1A3 88.4 nM () | PDE1B 8.48 nM () | PDE1C 12.2 nM () | PDE5A2 81.9 nM () |
|
体外研究 (In Vitro) | IMR-687 inhibits PDE9A with more than 800-fold greater potency than PDE1A3, PDE1B, PDE1C, PDE5A2, with IC50values of 88.4 μM, 8.48 μM, 12.2 μM, and 81.9 μM, respectively[1]. IMR-687 (0.1-10 μM) treatment in erythroid K562 cells for 72 hours induces hemoglobin (HbF) in a dose-dependent manner[1]. IMR-687 (0.03-10 μM) treatment for 6 hours in erythroid K562 cells increases cGMP in a dose-dependent manner[1].
|
体内研究 (In Vivo) | IMR-687 (30 mg/kg/day; after 30 days of treatment) shows a greater than 3-fold in the percent of HbF+F-cells (8.4% in vehicle treated and 27.3% in IMR-687 treated) and a corresponding 2-fold decrease in sickled red blood cells (56.3% in vehicle treated and 24.4% in IMR-687 treated)[1].
Animal Model: | HbSS-Townes mice on a 129/B6 background (10-12 weeks old)[1] | Dosage: | 30 mg/kg | Administration: | Dosed daily by gavage for 30 days | Result: | Resulted in fetal hemoglobin (HbF) induction, reduced hemolysis and reduced reticulocytosis. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(253.50 mM;Need ultrasonic) 配制储备液 1 mM | 2.5350 mL | 12.6752 mL | 25.3505 mL | 5 mM | 0.5070 mL | 2.5350 mL | 5.0701 mL | 10 mM | 0.2535 mL | 1.2675 mL | 2.5350 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|